Semler Scientific (SMLR) vs. Its Rivals Critical Contrast

Semler Scientific (OTCMKTS: SMLR) is one of 47 publicly-traded companies in the “Electromedical equipment” industry, but how does it contrast to its rivals? We will compare Semler Scientific to similar companies based on the strength of its analyst recommendations, valuation, profitability, risk, earnings, dividends and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Semler Scientific and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Semler Scientific 0 0 2 0 3.00
Semler Scientific Competitors 189 559 1131 46 2.54

Semler Scientific currently has a consensus target price of $44.00, suggesting a potential upside of 53.04%. As a group, “Electromedical equipment” companies have a potential upside of 28.68%. Given Semler Scientific’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Semler Scientific is more favorable than its rivals.

Institutional and Insider Ownership

0.8% of Semler Scientific shares are held by institutional investors. Comparatively, 41.9% of shares of all “Electromedical equipment” companies are held by institutional investors. 13.9% of Semler Scientific shares are held by company insiders. Comparatively, 14.9% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Semler Scientific and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Semler Scientific $12.45 million -$1.51 million -102.68
Semler Scientific Competitors $1.25 billion $101.33 million -18.70

Semler Scientific’s rivals have higher revenue and earnings than Semler Scientific. Semler Scientific is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Semler Scientific has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Semler Scientific’s rivals have a beta of 1.57, suggesting that their average stock price is 57% more volatile than the S&P 500.

Profitability

This table compares Semler Scientific and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Semler Scientific 19.66% -982.53% 74.53%
Semler Scientific Competitors -126.74% -112.59% -27.36%

Summary

Semler Scientific rivals beat Semler Scientific on 8 of the 13 factors compared.

About Semler Scientific

Semler Scientific, Inc. develops, manufactures, and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition; and WellChec, a multi-test service platform to evaluate patients with various chronic diseases. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as organizations, including healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry; and other healthcare organizations, such as risk assessment groups and other home healthcare providers. It offers its products through salespersons and distributors. Semler Scientific, Inc. was founded in 2007 and is headquartered in San Jose, California.

Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply